EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis

Dietrich von Kuenssberg Jehle, Raheed Sunesra, Shania M Williams, Nathaniel J Bilby, Krishna K Paul iD, Kelcie Hill

Therapeutic Advances in Pulmonary and Critical Care Medicine · 2026-03 · 21

DOI: 10.1177/29768675251413432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Pulmonary and Critical Care Medicine, online erschienen am 03.03.2026. Verfasst von Dietrich von Kuenssberg Jehle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, The University of Texas at Galveston, Galveston, TX, USA. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Institute for Translational Sciences, University of Texas Medical Branch.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirmatrelvir/Ritonavir (nir/rit) is an antiviral combination, often sold under the brand name Paxlovid, used to treat COVID-19, particularly in high-risk individuals. Numerous COVID-19 treatments exist, but clinical studies have reported conflicting data on their efficacy, particularly in unvaccinated patients.

Objectives

This study aims to compare 28-day mortality, hospitalization, intensive care unit (ICU) admission, observation status, and hypoxia rates among unvaccinated COVID-19 patients treated with nir/rit in the emergency department (ED) versus those who did not receive nir/rit.

Design

This retrospective, propensity-matched cohort study utilized the TriNetX database, which included records of 112 million patients from 64 academic medical centers and healthcare organizations across the U.S. The study period was 2022–2024.

Methods

The treatment cohort consisted of COVID-19-unvaccinated ED patients aged 18 and above who tested positive for COVID-19 via RNA test and were administered nir/rit on the same day. Patients admitted for observation or inpatient care on the same day were excluded. Outcomes assessed within 28 days post-ED diagnosis included mortality, ICU admission, inpatient hospitalization, observation status, and hypoxia (O 2 saturation ≤90%). Propensity score matching adjusted for demographics and 21 pre-existing conditions associated with COVID-19 severity and mortality.

Results

A total of 194 181 unvaccinated COVID-19 patients were identified, with 14 799 receiving nir/rit and 179 382 not receiving it. After propensity matching, 14 799 patients were included in each cohort. Paxlovid treatment was associated with lower mortality (risk ratios [RR] = 0.28, P < .001), fewer ICU admissions (RR = 0.53, P = .01), decreased inpatient visits (RR = 0.40, P < .001), reduced observation status (RR = 0.36, P = .004), and less hypoxia (RR = 0.49, P < .001). Trends were similar before propensity matching.

Conclusions

Nir/rit treatment in unvaccinated adults diagnosed with COVID-19 in the ED is associated with significantly lower mortality, ICU admissions, hospitalizations, observation status, and hypoxia, supporting its use in this patient population.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Nirmatrelvir/ritonaviremergency departmenthospitalizationvaccination

Autor:innen und Institutionen

  • Department of Emergency Medicine, The University of Texas at Galveston, Galveston, TX, USA.

ORCID-Profile: Krishna K Paul

Förderung

  • NCATS NIH HHS
  • Institute for Translational Sciences, University of Texas Medical Branch

Zitieren

APA

Jehle, D. V. K., Sunesra, R., Williams, S. M., Bilby, N. J., Paul, K. K., & Hill, K. (2026). Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. Therapeutic Advances in Pulmonary and Critical Care Medicine, 21. https://doi.org/10.1177/29768675251413432

Vancouver

Jehle DVK, Sunesra R, Williams SM, Bilby NJ, Paul KK, Hill K. Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. Therapeutic Advances in Pulmonary and Critical Care Medicine. 2026;21. doi:10.1177/29768675251413432

BibTeX
@article{Jehle2026,
  author = {Jehle, Dietrich von Kuenssberg and Sunesra, Raheed and Williams, Shania M and Bilby, Nathaniel J and Paul, Krishna K and Hill, Kelcie},
  title = {Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis},
  journal = {Therapeutic Advances in Pulmonary and Critical Care Medicine},
  year = {2026},
  volume = {21},
  doi = {10.1177/29768675251413432}
}
Kostenlos starten →